Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Panobinostat may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This phase II trial is studying the side effects of panobinostat and to see how well
it works in treating patients with relapsed or refractory acute lymphoblastic leukemia or
acute myeloid leukemia.